Aster DM Healthcare reports acquisition of 24.5 million shares, raising stake to 29.7%

What Aster DM Healthcare announced

Aster DM Healthcare Ltd filed a Regulation 29(1) disclosure on 14 July 2026, revealing that BCP Asia II Topco IV Pte Ltd together with seven persons acting in concert (PACs) have acquired a substantial block of shares in its subsidiary, Aster DM Quality Care Limited (formerly Aster DM Healthcare Limited). The acquisition consists of 24,49,96,597 equity shares, representing 28.11% of the subsidiary’s voting capital at the time of purchase. After the allotment, the acquirer’s total holding rises to 29.71%.

"The acquisition was effected pursuant to the Scheme of Amalgamation approved by the National Company Law Tribunal on 19 June 2026."

Details of the acquisition

The share purchase was executed under a Scheme of Amalgamation between Quality Care India Limited (the Transferor) and Aster DM Healthcare Limited (the Transferee). The scheme, sanctioned by the Hon’ble National Company Law Tribunal on 19 June 2026, stipulated a share‑exchange ratio of 977 equity shares of the Transferee for every 1,000 equity shares held in the Transferor.

Under the scheme, Aster DM Quality Care Limited allotted 24,49,96,597 fully paid‑up equity shares of Rs 10 each to BCP Asia II Topco IV Pte Ltd on 13 July 2026. No warrants, convertible securities, or encumbered shares were part of the transaction.

Parties involved

Shareholding before and after

The transaction did not involve any encumbrance (pledge, lien, or non‑disposal undertaking) and no virtual shares (VRs) or warrants were issued.

Shareholding impact

Prior to the scheme, BCP Asia II Topco IV and its PACs owned approximately 2.69% of Aster DM Quality Care Ltd’s voting capital. The allotment of 24.5 million shares increased their stake to 29.71%, making them a significant shareholder block but still short of a controlling interest (which would require >50%).

The increase in total equity share capital from 51.81 million to 87.17 million shares reflects the dilution effect on existing shareholders, as the new shares were issued rather than purchased from the market. However, the filing does not disclose any cash consideration; the transaction was purely a share‑swap under the court‑approved scheme.

Key facts at a glance

Why this matters for investors

The disclosure signals a substantial change in the ownership structure of Aster DM Quality Care Ltd, the quality‑care arm of the group. While the acquirer’s 29.71% stake does not confer outright control, it gives the PACs a sizable voting bloc that could influence board composition, strategic decisions, and dividend policy.

For existing shareholders of Aster DM Healthcare Ltd, the dilution of the subsidiary’s equity may affect the valuation of the holding in Aster DM Quality Care Ltd on the consolidated balance sheet. The increase in share count could also impact earnings per share (EPS) calculations for the subsidiary, depending on how the group allocates profits.

Regulatory-wise, the filing under SEBI’s Substantial Acquisition of Shares & Takeovers (SAST) regulations means the transaction has met the disclosure thresholds and will be monitored for any further share‑holding changes that could trigger additional compliance requirements, such as a mandatory open‑offer if the acquirer crosses the 25% threshold (which it has, but the filing indicates compliance with the scheme’s conditions).

Conclusion

Aster DM Healthcare Ltd’s subsidiary, Aster DM Quality Care Ltd, has issued 24.5 million new equity shares to BCP Asia II Topco IV Pte Ltd and associated persons, raising their combined voting stake to 29.71%. The allotment was executed under a court‑approved scheme of amalgamation with a defined share‑exchange ratio. While the transaction dilutes existing shareholders, it does not immediately alter control of the subsidiary. Further regulatory approvals or shareholder actions may be required if the acquirer seeks to increase its stake beyond the current level.

---

FAQs

1. What percentage of Aster DM Quality Care Ltd does the acquirer now hold? The acquirer and its PACs hold 29.71% of the subsidiary’s voting capital after the share allotment.

2. How were the new shares issued? The shares were allotted under a Scheme of Amalgamation approved by the National Company Law Tribunal, using a share‑exchange ratio of 977:1,000.

3. Did the transaction involve any cash payment? The filing does not disclose any cash consideration; the acquisition was effected through a share‑swap as per the scheme.

4. Will this trigger any mandatory open‑offer under SEBI rules? The filing is made under SEBI (SAST) Regulation 29(1). Since the acquirer’s holding exceeds 25%, the scheme’s terms and any related approvals would determine whether an open‑offer is required. The filing itself does not specify an open‑offer.

5. What is the total equity share capital of the target after the transaction? Post‑transaction, Aster DM Quality Care Ltd’s equity share capital stands at 871,672,439 shares.

6. Are there any encumbered shares or warrants involved? No. The disclosure states that there are zero encumbered shares, virtual shares, or warrants associated with the acquisition.